Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kay

Showing results (131-140 of 172) with videos related to

Pageof 18
Sort By:
Annals of the Rheumatic Diseases|June 11, 2014
Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammationChristian Schmidt-Lauber, Lukas Bossaller, Hani H Abujudeh, et al.
Arthritis and Rheumatism|April 3, 2008
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, et al.
Annals of the Rheumatic Diseases|March 31, 2012
Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160Josef S Smolen, Jonathan Kay, Robert B M Landewé, et al.
Rheumatology and Therapy|June 1, 2021
Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative StudyCatherine E Dube, Kate L Lapane, Katarina A Ferrucci, et al.
Rheumatology (Oxford, England)|April 17, 2015
Quality indicators in rheumatoid arthritis: results from the METEOR databaseVictoria Navarro-Compán, Josef S Smolen, Tom W J Huizinga, et al.
Oncotarget|June 3, 2015
Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancerNelma Pertega-Gomes, Jose R Vizcaino, Sergio Felisbino, et al.
ACR Open Rheumatology|June 11, 2020
Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis SurveyWoojin Joo, Christopher V Almario, Mariko Ishimori, et al.
RMD Open|April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2009
Nephrogenic systemic fibrosis: a pathologic study of autopsy casesAashiyana F Koreishi, Rosalynn M Nazarian, Adam J Saenz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
Pageof 18

Showing results (131-140 of 172) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|June 11, 2014
Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammationChristian Schmidt-Lauber, Lukas Bossaller, Hani H Abujudeh, et al.
Arthritis and Rheumatism|April 3, 2008
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, et al.
Annals of the Rheumatic Diseases|March 31, 2012
Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160Josef S Smolen, Jonathan Kay, Robert B M Landewé, et al.
Rheumatology and Therapy|June 1, 2021
Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative StudyCatherine E Dube, Kate L Lapane, Katarina A Ferrucci, et al.
Rheumatology (Oxford, England)|April 17, 2015
Quality indicators in rheumatoid arthritis: results from the METEOR databaseVictoria Navarro-Compán, Josef S Smolen, Tom W J Huizinga, et al.
Oncotarget|June 3, 2015
Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancerNelma Pertega-Gomes, Jose R Vizcaino, Sergio Felisbino, et al.
ACR Open Rheumatology|June 11, 2020
Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis SurveyWoojin Joo, Christopher V Almario, Mariko Ishimori, et al.
RMD Open|April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2009
Nephrogenic systemic fibrosis: a pathologic study of autopsy casesAashiyana F Koreishi, Rosalynn M Nazarian, Adam J Saenz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
Pageof 18